NOTICE OF AN EXTRA GENERAL MEETING OF SHAREHOLDERS
Press Release, Stockholm, Sweden, February 25, 2008 - Diamyd Medical AB
(www.omxgroup.com, ticker: DIAM B; www.otcqx.com, ticker DMYDY)
Diamyd Medical announced today a Notice of an Extra General Meeting of
Shareholders on Monday March 10, 2008, at 3:00 PM, in the Company's premises,
Linnégatan 89B, Stockholm, Sweden.
Shareholders who wish to attend the Extra General Meeting must:
• be recorded in the Company's register of shareholders, held by the VPC (the
Swedish Securities Register Center) by March 4, 2008
• notify the Company of their intention to attend no later than 4:00 pm March 4,
2008 per phone: +46 8 661 0026 or per E-mail: investor.relations@diamyd.com.
With the notification, name, address, phone number, social security
number/national tax ID number, number of shares and name of agent should be
stated.
Shareholders whose shares are registered in the name of a nominee through the
trust department of a bank or similar institution must, in order to be entitled
to participate in the Extra General Meeting, request that their shares are
temporarily registered in their own names in the register of shareholders
maintained by VPC. Such registration must be effective before March 4, 2008.
Agenda
1. Opening of the meeting
2. Election of the Chairman of the Extra General Meeting of Shareholders
3. Drawing up and approval of the voting list
4. Approval of the Agenda
5. Election of secretary and two persons to attest to the accuracy of the
minutes
6. Decision on whether proper notice of the Extra General Meeting has been made
7. The Board of Directors proposal of Authorization
8. Closing the meeting
The Board of Directors proposal for Authorization (item 7)
The number of outstanding shares in the Company is 9,910,570 of which 561,671 of
Series A (one vote) and 9,348,899 of Series B (1/10 vote). The number of votes
amounts to 1,496,560.9 of which 561,671 are A-shares and 934,889.9 are B-shares.
The Board of Directors proposal for authorization on one or several occasions
before the next Annual Shareholders' Meeting, with or without consideration of
the preferential shareholder rights to issue 91,000 shares of series B and
warrants which will give the right to subscribe for 991,000 B-shares. The
authorization is proposed to be valid for acquiring whole or parts of companies,
assets, and cash or for settlements or other conditions as stated in chapter 2
§5 second paragraph 1-3 and 5 in the Companies Act. After full execution of the
authorization of issuing shares in combination with the authorization given at
the Annual Shareholders' Meeting the dilution is calculated to 10 percent of the
share capital, based on the total number of shares. After full execution of the
authorization of the warrants and if they are fully subscribed, the dilution is
calculated to additional 10 percent.
The full description of the proposal of the Board of Directors is available at
the main office of Diamyd Medical: Linnégatan 89B, Stockholm, Sweden. At request
this documentation can be sent for free to shareholders that state their full
mailing address.
For further information, please contact:
Stockholm office
Elisabeth Lindner
CEO and President
+46 8 661 0026
elisabeth.lindner@diamyd.com
Stockholm office
Anders Essen-Möller
Chairman
+46 8 661 0026
anders.essen-moller@diamyd.com
Pittsburgh office
Michael Christini
President
+1 412 770 1310
michael.christini@diamyd.com
Diamyd Medical AB (publ). Linnégatan 89 B, SE-115 23 Stockholm, Sweden. Tel: +46
8 661 00 26, fax: +46 8 661 63 68 or E-mail: info@diamyd.com. VATno:
SE556530-142001.
About Diamyd Medical
Diamyd Medical is a biopharmaceutical company developing treatments for diabetes
and its complications. The company's furthest developed project is the GAD-based
drug Diamyd® for autoimmune diabetes for which Phase III studies are planned.
Diamyd® has demonstrated significant and positive results in Phase II clinical
trials in Sweden.
GAD65, a major autoantigen in autoimmune diabetes, is the active substance in
Diamyd. GAD65 is also an enzyme that converts the excitatory neurotransmitter
glutamate to the inhibitory transmitter GABA. In this context, GAD may have an
important role not only in diabetes but also in several central nervous
system-related diseases. Diamyd Medical has an exclusive worldwide license from
the University of California at Los Angeles regarding the therapeutic use of the
GAD65 gene.
Diamyd Medical has sublicensed its UCLA GAD Composition of Matter license to
Neurologix, Inc. in Fort Lee, New Jersey for treatment of Parkinson's disease.
Other projects comprise drug development within therapeutic gene transfer using
the exclusively licensed and patent protected Nerve Targeting Drug Delivery
System (NTDDS). The company's lead NTDDS projects include enkephalin and GAD for
chronic pain, e.g., diabetes pain or cancer pain.
Diamyd Medical has offices in Stockholm, Sweden and Pittsburgh, PA. The Diamyd
Medical share is quoted on the Stockholm Nordic Exchange in Sweden (NOMX ticker:
DIAM B) and on the OTCQX-list in the United States (ticker: DMYDY) administered
by the Pink Sheets and the Bank of New York (PAL). Further information is
available at www.diamyd.com.
Disclaimer: This document contains certain "statements" relating to present
understandings, future events and future performance, including statements
relating to the progress, timing and completion of our research, development and
clinical trials; our ability to market, commercialize and achieve market
acceptance for product candidates; and our current and future strategic partner
relationships. These statements can be affected by inaccurate assumptions or by
known or unknown risks and uncertainties. Diamyd Medical undertakes no
obligation to publicly update such statements, whether because of new
information, future events or otherwise, nor does Diamyd Medical give any
guarantees that the statements, given or implied, are correct. This document is
a translation from the Swedish original. No guarantees are made that the
translation is free from errors.
